Alcoholism Treatment by Disulfiram and Community Reinforcement Therapy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Addictions and the Brain
9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center. -
Medications and Alcohol Craving
Medications and Alcohol Craving Robert M. Swift, M.D., Ph.D. The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce craving; these include naltrexone (ReVia™), acamprosate, and tiapride. The remaining medication, disulfiram (Antabuse®), may also possess some anticraving activity. Additional medications that have been investigated include ritanserin, which has not been shown to decrease craving or drinking levels in humans, and ondansetron, which shows promise for treating early onset alcoholics, who generally respond poorly to psychosocial treatment alone. Use of anticraving medications in combination (e.g., naltrexone plus acamprosate) may enhance their effectiveness. Future studies should address such issues as optimal dosing regimens and the development of strategies to enhance patient compliance. KEY WORDS: AOD (alcohol and other drug) craving; anti alcohol craving agents; alcohol withdrawal agents; drug therapy; neurobiological theory; alcohol cue; disulfiram; naltrexone; calcium acetylhomotaurinate; dopamine; serotonin uptake inhibitors; buspirone; treatment outcome; reinforcement; neurotransmitters; patient assessment; literature review riteria for defining alcoholism Results of craving research are often tions (i.e., pharmacotherapy) to improve vary widely. Most definitions difficult to interpret, -
Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum
International Journal of Environmental Research and Public Health Review Mechanisms of Ethanol-Induced Cerebellar Ataxia: Underpinnings of Neuronal Death in the Cerebellum Hiroshi Mitoma 1,* , Mario Manto 2,3 and Aasef G. Shaikh 4 1 Medical Education Promotion Center, Tokyo Medical University, Tokyo 160-0023, Japan 2 Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000 Charleroi, Belgium; [email protected] 3 Service des Neurosciences, University of Mons, 7000 Mons, Belgium 4 Louis Stokes Cleveland VA Medical Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44022, USA; [email protected] * Correspondence: [email protected] Abstract: Ethanol consumption remains a major concern at a world scale in terms of transient or irreversible neurological consequences, with motor, cognitive, or social consequences. Cerebellum is particularly vulnerable to ethanol, both during development and at the adult stage. In adults, chronic alcoholism elicits, in particular, cerebellar vermis atrophy, the anterior lobe of the cerebellum being highly vulnerable. Alcohol-dependent patients develop gait ataxia and lower limb postural tremor. Prenatal exposure to ethanol causes fetal alcohol spectrum disorder (FASD), characterized by permanent congenital disabilities in both motor and cognitive domains, including deficits in general intelligence, attention, executive function, language, memory, visual perception, and commu- nication/social skills. Children with FASD show volume deficits in the anterior lobules related to sensorimotor functions (Lobules I, II, IV, V, and VI), and lobules related to cognitive functions (Crus II and Lobule VIIB). Various mechanisms underlie ethanol-induced cell death, with oxidative stress and Citation: Mitoma, H.; Manto, M.; Shaikh, A.G. Mechanisms of endoplasmic reticulum (ER) stress being the main pro-apoptotic mechanisms in alcohol abuse and Ethanol-Induced Cerebellar Ataxia: FASD. -
Alcohol-Medication Interactions: the Acetaldehyde Syndrome
arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Borja-Oliveira, J Pharmacovigilance 2014, 2:5 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000145 Review Article Open Access Alcohol-Medication Interactions: The Acetaldehyde Syndrome Caroline R Borja-Oliveira* University of São Paulo, School of Arts, Sciences and Humanities, São Paulo 03828-000, Brazil *Corresponding author: Caroline R Borja-Oliveira, University of São Paulo, School of Arts, Sciences and Humanities, Av. Arlindo Bettio, 1000, Ermelino Matarazzo, São Paulo 03828-000, Brazil, Tel: +55-11-30911027; E-mail: [email protected] Received date: August 21, 2014, Accepted date: September 11, 2014, Published date: September 20, 2014 Copyright: © 2014 Borja-Oliveira CR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Medications that inhibit aldehyde dehydrogenase when coadministered with alcohol produce accumulation of acetaldehyde. Acetaldehyde toxic effects are characterized by facial flushing, nausea, vomiting, tachycardia and hypotension, symptoms known as acetaldehyde syndrome, disulfiram-like reactions or antabuse effects. Severe and even fatal outcomes are reported. Besides the aversive drugs used in alcohol dependence disulfiram and cyanamide (carbimide), several other pharmaceutical agents are known to produce alcohol intolerance, such as certain anti-infectives, as cephalosporins, nitroimidazoles and furazolidone, dermatological preparations, as tacrolimus and pimecrolimus, as well as chlorpropamide and nilutamide. The reactions are also observed in some individuals after the simultaneous use of products containing alcohol and disulfiram-like reactions inducers. -
AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM and ACAMPROSATE in the TREATMENT of ALCOHOL DEPENDENCE AVINASH DE SOUSA* and ALAN DE SOUSA
Alcohol & Alcoholism Vol. 40, No. 6, pp. 545–548, 2005 doi:10.1093/alcalc/agh187 Advance Access publication 25 July 2005 AN OPEN RANDOMIZED STUDY COMPARING DISULFIRAM AND ACAMPROSATE IN THE TREATMENT OF ALCOHOL DEPENDENCE AVINASH DE SOUSA* and ALAN DE SOUSA Get Well Clinic And Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, Maharashtra State, India (Received 11 March 2005; first review notified 6 June 2005; in final revised form 21 June 2005; accepted 2 July 2005; advance access publication 25 July 2005) Abstract — Aims: To compare the efficacy of acamprosate (ACP) and disulfiram (DSF) for preventing alcoholic relapse in routine clinical practice. Methods: One hundred alcoholic men with family members who would encourage medication compliance and accom- pany them for follow-up were randomly allocated to 8 months of treatment with DSF or ACP. Weekly group psychotherapy was also available. The psychiatrist, patient, and family member were aware of the treatment prescribed. Alcohol consumption, craving, and adverse events were recorded weekly for 3 months and then fortnightly. Serum gamma glutamyl transferase was measured at the start Downloaded from https://academic.oup.com/alcalc/article/40/6/545/125907 by guest on 27 September 2021 and the end of the study. Results: At the end of the trial, 93 patients were still in contact. Relapse (the consumption of >5 drinks/40 g of alcohol) occurred at a mean of 123 days with DSF compared to 71 days with ACP (P = 0.0001). Eighty-eight per cent of patients on DSF remained abstinent compared to 46% with ACP (P = 0.0002). -
(12) Patent Application Publication (10) Pub. No.: US 2013/0165511 A1 Lederman Et Al
US 2013 O165511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0165511 A1 Lederman et al. (43) Pub. Date: Jun. 27, 2013 (54) TREATMENT FOR COCANE ADDICTION Publication Classification (75) Inventors: Seth Lederman, NEW York, NY (US); (51) Int. Cl. Herbert Harris, Chapel Hill, NC (US) A63/37 (2006.01) A63/6 (2006.01) (73) Assignee: TONIX Pharmaceuticals Holding (52) U.S. Cl. Corp, New York, NY (US) CPC ............... A61K 31/137 (2013.01); A61K3I/I6 (2013.01) (21) Appl. No.: 13/820,338 USPC ........................................... 514/491; 514/654 (22) PCT Fled: Aug. 31, 2011 (57) ABSTRACT (86) PCT NO.: PCT/US11/O1529 A novel pharmaceutical composition is provided for the con S371 (c)(1), trol of stimulant effects, in particular treatment of cocaine (2), (4) Date: Mar. 1, 2013 addiction, or further to treatment of both cocaine and alcohol dependency, including simultaneous therapeutic dose appli Related U.S. Application Data cation or a single dose of a combined therapeutically effective (60) Provisional application No. 61/379,095, filed on Sep. composition of disulfiram and selegiline compounds or phar 1, 2010. maceutically acceptable non-toxic salt thereof. US 2013/01655 11 A1 Jun. 27, 2013 TREATMENT FOR COCANE ADDCTION the United States in 2005. In the sense of this invention the term “addiction' may be defined as a compulsive drug taking CROSS-REFERENCE TO RELATED or abuse condition related to “reward’ system of the afflicted APPLICATIONS: patient. The treatment of cocaine addiction or dependency 0001. The present application which claims priority from has targeted a lowering of dopaminergic tone to help decrease U.S. -
Alcohol Dependence, Withdrawal, and Relapse
Alcohol Dependence, Withdrawal, and Relapse Howard C. Becker, Ph.D. Continued excessive alcohol consumption can lead to the development of dependence that is associated with a withdrawal syndrome when alcohol consumption is ceased or substantially reduced. This syndrome comprises physical signs as well as psychological symptoms that contribute to distress and psychological discomfort. For some people the fear of withdrawal symptoms may help perpetuate alcohol abuse; moreover, the presence of withdrawal symptoms may contribute to relapse after periods of abstinence. Withdrawal and relapse have been studied in both humans and animal models of alcoholism. Clinical studies demonstrated that alcoholdependent people are more sensitive to relapse provoking cues and stimuli than nondependent people, and similar observations have been made in animal models of alcohol dependence, withdrawal, and relapse. One factor contributing to relapse is withdrawalrelated anxiety, which likely reflects adaptive changes in the brain in response to continued alcohol exposure. These changes affect, for example, the body’s stress response system. The relationship between withdrawal, stress, and relapse also has implications for the treatment of alcoholic patients. Interestingly, animals with a history of alcohol dependence are more sensitive to certain medications that impact relapselike behavior than animals without such a history, suggesting that it may be possible to develop medications that specifically target excessive, uncontrollable alcohol consumption. KEY WORDS: Alcoholism; alcohol dependence; alcohol and other drug (AOD) effects and consequences; neuroadaptation; AOD withdrawal syndrome; AOD dependence relapse; pharmacotherapy; human studies; animal studies he development of alcohol expectations about the consequences of drinking (Koob and Le Moal 2008). dependence is a complex and alcohol use. -
Consent for Treatment with Disulfiram
CONSENT FOR TREATMENT WITH DISULFIRAM • Disulfiram (Antabuse) is a medication that is used to help prevent relapse to alcohol. • The body is not able to process alcohol while taking disulfiram. This includes even very small doses that may be absorbed from perfume, hand sanitizer, food items (dressings, vinegars, marinades, sauces, extracts, etc.) and alcoholic beverages. It is important to check labels of items that will go in or on your body. • Disulfiram should NOT be taken if you have consumed alcohol within the past 12 hours. • A disulfiram-alcohol reaction may include: trouble breathing, throbbing pain in head and neck, nausea, vomiting, sweating, thirst, palpitations, weakness, dizziness, blurred vision, and confusion. Severe reactions may involve respiratory failure, heart failure, unconsciousness, seizure, and death. • The larger the dose of the alcohol, the stronger the disulfiram-alcohol effect. The reaction can last from 30 minutes to several hours, or as long as it takes for the alcohol to be metabolized. • Disulfiram-alcohol reaction may occur for up to 2 weeks after stopping medication. • This medication can affect your liver. Blood will be drawn before starting treatment, again soon after starting treatment, and then as needed to make sure your liver is healthy. Tell your treatment team or seek emergency care if you develop any of these symptoms: o Yellowing of the skin or eyes o Dark urine o White stool or diarrhea o Stomach pain or loss of appetite o More tired than normal • Allergic reactions can happen when taking disulfiram. Alert your treatment team or get immediate medical help if you have any of these symptoms: o Skin rash o Chest pain o Trouble breathing or wheezing o Dizziness or fainting o Swelling of eyes, mouth, tongue, or face • The most common side effect of disulfiram is drowsiness, but severe adverse reactions have occurred in some individuals. -
Alcohol Abuse and Acute Lung Injury and Acute Respiratory Distress
Journal of Anesthesia & Critical Care: Open Access Review Article Open Access Alcohol abuse and acute lung injury and acute respiratory distress syndrome Introduction Volume 10 Issue 6 - 2018 Alcohol is one of the most commonly used and abused beverage Fadhil Kadhum Zwer Aliqa worldwide. Alcohol is known to have numerous systemic health Private clinic practice, Iraq effects, including on the liver and central nervous system. From a respiratory standpoint, alcohol abuse has long been associated with Correspondence: Fadhil Kadhum Zwer Aliqaby, Private clinic practice, Iraq, Email an increased risk of pneumonia. More recently, alcohol abuse has been strongly linked in epidemiologic studies to development of Received: December 11, 2017 | Published: November 28, ARDS in at-risk patients. The first demonstration of an association 2018 between chronic alcohol abuse and ARDS was made by Moss et al, who retrospectively examined 351 patients at risk for ARDS.1 In this subsequent decreased phagocytosis and bacterial killing. Chronic cohort, 43% of patients who chronically abused alcohol developed alcohol use is similarly associated with altered neutrophil function and ARDS compared to only 22% of those who did not abuse alcohol, decreased superoxide production. Interestingly, chronic alcohol use with the effect most pronounced in patients with sepsis. This study decreases levels of granulocyte/macrophage colony stimulating factor was limited by its retrospective design, particularly since this design (GM-CSF) receptor and signaling in lung epithelium, which has been required that alcohol use history be obtained by chart review and shown to result in defective alveolar macrophage maturation. The documented history; furthermore, this study did not adjust for net effect of these abnormalities is an increased pulmonary bacterial concomitant cigarette smoking. -
PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants -
Nano-Enabled Disulfiram for Cancer Therapy
Nano-enabled disulfiram for cancer therapy Erazuliana Abd Kadir A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy of University College London UCL School of Pharmacy 29-39 Brunswick Square London, WC1N 1AX February 2017 Declaration The thesis describes the research conducted in the UCL School of Pharmacy, University College London between 2012 and 2016 under the supervision of Professor Andreas Schätzlein. I, Erazuliana Abd Kadir, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signature : Date : 17th February 2017 ii ABSTRACT The hypothesis was that encapsulation of labile disulfiram (DS) in a high capacity nanoemulsion stabilized by quaternary ammonium palmitoyl glycol chitosan (GCPQ) could protect DS from degradation in the blood and increase its delivery to tumours. GCPQ was synthesized from glycol chitosan and characterized. GCP20Q11 polymer was chosen to be incorporated with DS in soybean oil into homogenous DS-GCP20Q11-E nanoemulsion. The nanoemulsions showed capability of oil-loading up to 50% v/v for a stable entrapment of high drug content. With increasing oil content (5 to 50%) the mean particle size increased, as did overall polydispersity (190 to 359 nm and 0.14 to 0.21, respectively). Transmission electron microscope (TEM) images showed existence of heterogeneous particles with a size below 100 nm. The drug load and colloidal stability were improved in lower oil-content formulations stored at low temperature. Formulations showed highly positive particle surface charge (51 mV at pH 4.50), proving the ionic stability of the individual particles. -
How Alcoholism & Alcohol Abuse Affects Low-Income Populations In
How Alcoholism & Alcohol Abuse Affects Low-Income Populations In Ohio www.WomanInRecovery.com Alexis Chapman • Addiction Recovery Advocate • Certified Professional Recovery Coach • Certified & Accredited Leadership Coach 8 years actively writing, publishing and contributing to the recovery industry • Collaborated and developed curriculum and resources for Sherry Gaba, LCSW, Psychotherapist, Life Coach and Certified Recovery Coach. Sherry was the go-to expert for Dr. Drew Pinsky’s Celebrity Rehab show on VH1. • Currently collaborating with Dr. Jean LaCour, Ph.D, CPP, CPC. Dr. LaCour is founder and CEO of Net Institute Center for Addiction and Recovery Education. www.WomanInRecovery.com Look Familiar? www.WomanInRecovery.com Today We Will Cover • Overview of alcohol abuse and alcoholism. • How to recognize the signs of addiction • The impact of alcohol abuse on the brain • Review effective tools to handle those addicted and family members impacted by their addiction • State and county statistics regrading alcoholism and alcohol abuse in lower income populations • 5-point strategy for case managers and program staff working with clients who abuse alcohol or are alcoholics and family members impacted by their addiction • List of Ohio resources will be provided www.WomanInRecovery.com What’s The Difference? Binge Alcohol Drinking Abuse AUD Heavy Alcoholism Drinking http://www.hazeldenbettyford.org www.WomanInRecovery.com What’s The Difference? AUD: a medical Heavy Drinking: Binge disorder with drinking on 5 or more mild, moderate days in the